BioNTech's Twin Headwinds: A Founder Exodus and a Race Against the COVID Revenue Cliff

BioNTech enters a critical period with founder CEO departure, shrinking COVID revenue, and a high-stakes oncology pivot led by Pumitamig Phase 3 trials.

The German biotech is entering its most consequential period since the pandemic peak, with a leadership vacuum, a shrinking COVID franchise, and a high-stakes pivot to oncology all converging in a single month.

The Numbers Tell a Stark Story

BioNTech’s financial trajectory has flipped sharply. For the first quarter of 2026, analysts project a loss of $2.54 per share on revenue of roughly $220 million. That compares with over $1 billion in the prior quarter. The three-year revenue growth rate has cratered to minus 42.6%, according to GuruFocus. The stock, recently trading near $102, gives the company a market capitalization of about $26 billion.

The pressure is palpable. In euros, the shares sit at €86.60, roughly 15% below their 52-week high but well off the March trough of €72.50.

A Founder Exit Reshapes the C-Suite

The most dramatic development is the planned departure of CEO Ugur ?ahin and Chief Medical Officer Özlem Türeci by the end of 2026. The husband-and-wife team who steered BioNTech through the COVID vaccine triumph will leave to build a new company focused on next-generation mRNA technologies. BioNTech will retain a minority stake and rights to future milestones from that venture.

The timing is delicate. The founders’ exit coincides with a period when the company is burning cash on cancer research while its COVID revenue stream evaporates. The May 15 annual general meeting will be a key moment: shareholders will vote on expanding the supervisory board from six to eight members and authorizing new capital for 2026. Management will need to provide concrete answers on succession planning and the commercialization timeline for the oncology pipeline.

EMA Extends Comirnaty’s Reach — But It’s No Game Changer

On April 27, the European Medicines Agency’s CHMP recommended lowering the age threshold for several Comirnaty formulations. All 10-microgram variants targeting JN.1, KP.2, and LP.8.1 strains are now cleared for children as young as six months, down from the previous floor of five years. Infants aged six months to four years without a completed primary series will receive three doses: the first two three weeks apart, the third at least eight weeks after the second.

This is a meaningful expansion of the COVID franchise, but analysts view it as a stabilizing measure rather than a revenue catalyst. The real growth story lies elsewhere.

Pumitamig Takes Center Stage

The oncology pipeline is now BioNTech’s primary narrative. The bispecific antibody Pumitamig (BNT327) is being tested in nine Phase 3 trials. Data presented at the European Lung Cancer Congress showed a response rate of 53.3% and median overall survival of 27 months in certain non-small cell lung cancer patients. Median progression-free survival came in at 13.6 months.

That positions Pumitamig directly against Merck’s MK-2010, which posted response rates between 44% and 55% in the same indication. BioNTech is running seven Phase 3 studies with Pumitamig alone in first-line non-small cell lung cancer. The company’s target is to have 15 ongoing Phase 3 trials across its oncology pipeline by the end of 2026.

Wall Street’s Divided Verdict

The analyst community reflects the uncertainty. H.C. Wainwright rates the stock a “Buy” with a $130 price target, matching Bank of America’s recently raised target. BMO sets its target at $128. But Leerink Partners has cut its target to $94, citing concerns about the CTLA-4 antagonist Gotistobart.

GuruFocus estimates the fair value at roughly $90, suggesting the stock may be overvalued on historical metrics. The company’s return on capital stands at negative 8.9%, though it maintains substantial liquidity reserves.

The Calendar That Matters

May 5 brings the official first-quarter earnings release. Ten days later, the annual general meeting will force management to address the leadership transition and pipeline monetization strategy. Between the founder exodus, the EMA decision, and the clinical data flow, BioNTech is navigating a transformation that will define its post-pandemic identity.